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Abstract
IL-33, an IL-1 family member and ligand for the IL-1 receptor-related protein ST2, has been associated with induction of Th2
cytokines such as IL-4, IL-5, and IL-13. Here, we report that IL-33 can initiate IL-9 protein secretion in vitro in human CD4+ T
cells and basophils isolated from peripheral blood. TGF-b has been described as a critical factor for IL-9 induction in Th2
cells; however, we found that TGF-b also induces co-production of IL-9 in purified, naı ¨ve (.99%) CD4
+CD45RA
+C-
D45RO
2CD25
2 T cells differentiated towards a Th1 profile. Subsequently, it was demonstrated that TGF-b is important,
although not an absolute requirement, for IL-9 production in CD4+ T cells. IL-9 production by purified (.95%) human
basophils, cultured for 24 h with IL-3 or IL-33, was found, with a strong synergy between the two, likely to be explained by
the IL-3 upregulated ST2 expression. Collectively, these data indicate that barrier functioning cells are important for the
regulation of IL-9 production by immune cells in inflamed tissue.
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Introduction
A broad spectrum of pathogens activates innate immune
responses that direct a specific adaptive immune response.
Depending on the cytokine milieu and type of pathogen, naı ¨ve
CD4+ T cells differentiate into specialized subsets, such as Th1,
Th2, Th17, T follicular, or T regulatory (Treg), all important in
different stages of the immune response [1]. Each CD4+ T cell
subset is characterized by the expression of lineage-specific
transcription factors, and produces a repertoire of signature
cytokines, such as IFN-c or IL-4, IL-5 and IL-13 for Th1 and Th2
cells, respectively. A fine tuning of the cytokine profile acquired by
the differentiating T cells in the lymph node or other immune cells
in the tissue is hypothesized to take place after homing to inflamed
tissue, influenced by local alarming cytokines, such as IL-25, IL-
33, and thymic stromal lymphopoietin [2]. These alarming
cytokines may be released not only by immune cells, but also by
epithelial cells upon encountering allergens, helminth-derived
products, viruses, or other irritants causing stress [2]. IL-33 is
mainly secreted by lung barrier functional cells, such as fibroblasts,
epithelial cells, and endothelial cells [3]. IL-33 an IL-1 family
member together with IL-1b and IL-18 mediates its biological
effects via IL-1 receptor-like 1 (ST2) and has been reported to
trigger production of the main allergy signature cytokines IL-4, IL-
5, and IL-13 by Th2 cells, basophils, and mast cells [4–7]. It has
been hypothesized that IL-33 is released after tissue damage by,
for instance, allergens, resulting in necrotic cell death [8]; thus,
linking the release of IL-33 to an activation of the surrounding cells
such as T cells or basophils expressing ST2 [9].
In addition to the described alarming factors, the pleiotropic
cytokine TGF-b has been associated with differentiation of various
CD4+ T cell subsets, including Treg, Th9, and Th17; and TGF-b
has been described to be important in airway remodelling and
tissue repair [1,10]. In asthmatics, TGF-b mRNA expression was
increased in bronchial airways and it has been shown that
prolonged allergen challenge induces production of active TGF-b
in lung tissue [11]. TGF-b in relation to differentiation of CD4+ T
cells into a Th9 subset was first described by Schmitt et al., who
showed that TGF-b and IL-2 induce IL-9 in a subpopulation of
Th2 cells, later classified as Th9 cells [12]. Various cell types
involved in allergy and asthma are known to express the IL-9
receptor, however the physiological role of IL-9 is currently not
well understood [13]. Expression of IL-9 has been found to be
significantly increased in atopic patients compared to non-atopic
subjects, and, in addition, it has been suggested to be important in
chronic allergic inflammation [14,15].
Until recently, there has not been described a specific master
transcription factor for the Th9 subpopulation; however, in 2010
Chang et al. reported that PU.1 is expressed specifically in the IL-
4
lowIL-9
high population of Th2 cells, separating this subpopulation
into a distinct lineage [14]. The in vitro regulation of IL-9 in CD4+
T cell cultures has been found to be influenced by multiple
cytokines, including IL-1b, IL-2, IL-4, IL-6, IL-10, IL-21, IL-23,
IFN-a, IFN-b, and TGF-b [5,12,16,17].
The number of cytokines regulating IL-9 production in CD4+ T
cells is increasing in parallel with the number of CD4+ T subsets
that have been discovered to produce IL-9, including Th2, Th9,
and Th17 [5,16,17]. Here we report that IL-33 independent of
TGF-b upregulates IL-9 secretion in human in vitro differentiated
CD4+ cells. This may reflect a more general inflammatory
pathway, since our results also showed that IL-33 in synergy with
IL-3 induces secretion of IL-9 in in vitro cultured human basophils.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21695This might imply that IL-33 has an important role in the
regulation of IL-9 in the tissue immune cells.
Materials and Methods
Isolation of naı ¨ve CD4+ T cells and basophils
Cells used in this study originate from buffy coat fractions of
blood portions from anonymized donors, whose identity has been
anonymized for the researcher by the Blood Bank of the National
University Hospital Copenhagen (Copenhagen, DK).
PBMC were purified using lymphoprep density centrifuga-
tion and hemolysis of remaining erythrocytes was performed on
ice. The cells were washed twice with PBS
+ buffer (PBS without
Ca
2+ and Mg
2+) (Invitrogen) and supplemented with 0.5%
(vol./vol.) EDTA (Bie & Berntsen, Rødovre, DK) and 0.5%
(vol./vol.) human serum albumin (ZLB Behring GmbH,
Marburg, DE).
Using the Naive CD4+ T Cell Isolation Kit II (Miltenyi, Gladback,
DE), according to the manufacturer’s instructions, naı ¨ve
CD4
+CD45RA
+CD45RO
2CD25
2cells were magnetically isolated.
In short, PBMC were incubated with a cocktail of biotinylated
antibodies (Miltenyi), followed by labeling with magnetic anti-biotin-
coated microbeads for magnetic depletion. The cells were depleted
twice using new LS columns for each round of depletion, and
subsequently stained and depleted with the same cocktail of
biotinylated antibodies and anti-biotinylated microbeads to ensure a
purity of .99% CD4
+CD45RA
+CD45RO
2CD25
2 cells.
Basophils were purified from the PBMC fraction, as described
above without hemolysis, using the Basophil Isolation Kit II
(Miltenyi) according to the manufacturer’s protocol. In brief, Fc
receptor blocking reagent was applied along with biotin-conjugat-
ed antibodies. Following incubation, anti-Biotin magnetic beads
were added, and after a second incubation, the cells were washed
and applied to a LS column placed in a magnet. The basophils
Figure 1. TGF-b induces IL-9 secretion in Th1 and Th2 cells. Naı ¨ve CD4+ T cells were activated with fibroblast-bound anti-CD3/CD28 under
classical Th1 and Th2 conditions, with IL-12 and anti-IL-4 or IL-4, anti-IFN-c, and anti-IL-12 respectively for 5 days, restimulated at day 5 and split in
cultures with and without TGF-b or anti-TGF-b for 5 more days of stimulation. (A, B and C) Supernatant concentrations of IL-9, IL-5 and IFN-c at day 10
after restimulation with PMA and ionomycin for 6 h in the presence of Bref A for the last 4 h. Each donor is represented by a specific symbol and
connected with a line. Data are from four independent experiments, each with two donors. * p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0021695.g001
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the purification process the basophils were kept at temperatures
,8uC. The purity of the isolated basophils used for FACS analysis
of ST2 expression was 89.7% 68.8, whilst the purity of isolated
basophils used for multiplex analysis was 95.5% 60.8.
Cultures
Naı ¨ve CD4+ T cells were cultured at 37uCi n6 -o r4 8 - w e l lf l a t -
bottomed plates from Nunc (Roskilde, DK) in RPMI 1640 from Sigma
(Saint Louis, MO, USA) supplemented with 100 U/ml penicillin and
100 mg/ml streptomycin, 1 mM L-glutamine from Invitrogen (Carls-
bad, CA, USA), 50 mM b-mercaptoethanol (Sigma), and 5% (vol./vol.)
human AB serum from Righospitalet (Copenhagen, DK). The naı ¨ve
CD4+T cells, were cultured at 1*10‘5 cells per ml in 500 mlm e d i aa n d
supplemented with irradiated murine CD32-transfected fibroblasts
(162GC-7) by GAMMACELLE 2000 RH from AEK Risø (Risø, DK)
at a ratio of one fibroblast per five T cells, in the presence or absence of
the indicated human cytokines added day 0 and/or 5:10 ng/ml IL-4,
IL-12, and IL-33 from eBioscience (San Diego, CA, USA), 10 ng/ml
IL-2 Proleukin from Novartis (Auckland, AUS), and 10 ng/ml IL-1b,
IL-18, and TGF-b from Humanzyme (Chicago, IL, USA). Antibodies
used: 5 mg/ml anti-IL-12, and 5 mg/ml anti-PAN specific TGF-b from
R&D systems (Minneapolis, MN, USA), 10 mg/ml anti-IL-4 (MP4-
25D2), and 5 mg/ml anti-IFN-c (MD-1, eBioscience), 30 ng/ml anti-
CD3 (UCHT1), and 30 ng/ml anti-CD28 (CD28.2) from BD
Biosciences (Franklin Lakes, NJ, USA). The cultures were restimulated
day 5. At day 8, the cultures were split into two and medium was added
1:1 to obtain cultures for either quantitative RT-PCR (qRT-PCR) or
FACS and multiplex analysis.
Cultures for FACS and multiplex analysis were re-stimulated for
6 hours with 25 ng/ml 13-phorbol 12-myristate acetate (PMA),
and 1 mg/ml ionomycin, and for the last 4 hours of incubation
also 10 mg/ml Brefeldin A (Bref A) (Sigma).
Cell pellets for qRT-PCR analysis of mRNA were snap-frozen
in liquid nitrogen.
Human basophils were cultured at 37uC for 24 hours in RPMI
1640 from (Sigma) supplemented with 100 U/ml penicillin,
100 mg/ml streptomycin, and 1 mM L-glutamine (Invitrogen),
and 5% (vol./vol.) human AB serum (Righospitalet). Purified
basophils were resuspended in preheated media to a concentration
of 1*10
6 cells/ml, and cultured in 1.5 ml eppendorf tubes with
0.3 ml cell suspension in each tube. Concentration of IL-3 was
10 ng/ml (R&D), and IL-33 50 ng/ml (eBioscience). After 24 h of
culture, 200 ml of the cell suspension was used for FACS analysis
and the remaining cells were centrifugated at 1000 g for 5 min, the
supernatant was removed and saved for multiplex analysis, and the
pellet was snap-frozen in liquid nitrogen for qRT-PCR analysis.
All samples were stored at 280uC.
Multiplex supernatant analysis
Supernatants from the T cell cultures were assessed for the
cytokine secretion of; IL-4, IL-5, IL-9, IL-13, TGF-b1, and IFN-c,
and the supernatant from basophils for IL-4, IL-5, IL-9, and IL-13
secretion by multiplex magnetic bead assay (BioRad, Berkeley,
CA, USA), according to the manufacturer’s protocol, with the
exception of no acid activation in the TGF-b analysis. The
samples were analyzed on a Bio-Plex 200 System using Bio-Plex
Manager 5.0 (BioRad).
Flow cytometry
At day 10, the T cells were restimulated and subsequently
harvested and washed in PBS
+ and reconstituted in PBS without
Ca
2+ and Mg
2+ at a concentration of 1*10‘6 cells per ml. Staining
with a LIVE/DEAD fixable red dead cell stain kit (Invitrogen) was
performed according to the manufacturer’s protocol. The cells
were reconstituted in 100 ml PBS
+ and surface stained with anti-
CD4 conjugated with either PE-cy5 (PC5) or PE-cy7 (PC7), both
(OKT4) from Biolegend (San Diego, CA, USA) for 15 min in the
dark on a rocking table, at room temperature. The cells were
washed in PBS
+, fixed, and permeabilized with IntraPrep from
Beckman Coulter (Fullerton, CA, USA) according to the
manufacturer’s protocol, and subsequently stained according to
the surface procedure, using different mix of fluorescently labeled
antibodies against: anti-IL-9-PE (MH9A4), anti-IL-13- peridinin
chlorophyll protein complex (PerCP) (JES10-5A2), anti-IFN-c-
FITC (4S.B3), and anti-T-bet-FITC (4B10, Biolegend), anti-IL-4-
PE-cy7 (8D4-4), anti-GATA3-PE (TWAJ, eBioscience), anti-IL-5-
FITC (9906, R&D), and also anti-PU.1-Alexa 488 (9G7) from Cell
Signaling (Danvers, MA, USA). The cells were first gated on the
LIVE region, second the CD4+ region followed by analysis of
intracellular cytokines or transcription factors. A cutoff of 2% of
the isotype control was used for the surface and the transcription
factors, whereas the cytokines were primarily separated by gating
on populations.
To assess the purity of freshly isolated basophils, the cells were
resuspended to a concentration of 5*10
5 cells/ml in 100 ml PBS
+,
and surface stained with PC7-conjugated CD3, CD14, and CD19
(Biolegend) and CD56 (Beckman Coulter); and FITC-conjugated
FceRIa (Biolegend) for 30 min, at 4uC, in the dark. Basophils were
gated as FceRIa
+CD3
2CD14
2CD19
2CD56
2. In addition, both
freshly isolated and cultured basophils were stained with FITC-
conjugated ST2 (MBL) and mouse IgG1 (Beckman Coulter), and
expression of ST2 for all samples was compared to their respective
isotype control. Expression of ST2 at 24 h was analysed by
comparing the expression level of ST2 in the negative control
culture with that of the stimulated control cultures.
All labeled cells were analyzed by FACS using a Beckman Coulter
FC500 MPL flow cytometer with CXP software (Beckman Coulter).
Amine reactive compensation beads or compensation beads (Invitro-
gen) were used according to the manufacturer’s protocol for each
antibody for compensation of the FACS data prior to data analysis
using FlowJo from Treestar (Ashland, OR, USA).
RNA purification
RNA was purified using RNeasy mini kit from Qiagen (Hilden,
DE) according to the manufacturer’s protocol. RNA concentra-
tions were measured using an RNA determination kit on a Qubit
Flurometer (Invitrogen).
cDNA synthesis
0.5 or 0.1 mg total RNA from CD4+ cell or basophil cultures,
respectively, was mixed with 1 ml of 0.5 mg/ml oligo (dT)
Figure 2. TGF-b induces IL-9 expression in Th1 and Th2 cells. Naı ¨ve CD4+ T cells were activated with fibroblast-bound anti-CD3/CD28 under
classical Th1 and Th2 conditions, with IL-12 and anti-IL-4 or IL-4, anti-IFN-c, and anti-IL-12 respectively for 5 days, restimulated at day 5 and split in
cultures with and without TGF-b or anti-TGF-b for 5 more days of stimulation. (A, B, C, D, E and F) Percentage positive LIVE
+CD4+ cells for, respectively
IL-9, PU.1, IL-13, IFN-c, GATA-3, and T-bet at day 10 after restimulation with PMA and ionomycin for 6 h in the presence of Bref A for the last 4 h. Each
donor is represented by a symbol and connected with a line. Data are from four independent experiments, each with two donors.* p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0021695.g002
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minutes at 70uC to denature the RNA. The RNA was transcribed
to cDNA using Superscript II reverse transcriptase (Invitrogen) at
42uC for 50 minutes followed by heat inactivation of enzymes at
70uC for 10 min. The cDNA was stored at 220uC.
qRT-PCR
Relative mRNA expression levels were determined by qRT-
PCR using the ABI PRISM 7700 sequence detection system from
Applied Biosystems (Carlsbad, CA, USA). For each triplicate
qRT-PCR analysis, 1.5 ml cDNA was mixed with 12 ml water,
Figure 3. TGF-b induces IL-9 mRNA expression in Th1 and Th2 cells. Naı ¨ve CD4+ T cells were activated with fibroblast-bound anti-CD3/CD28
under classical Th1 and Th2 conditions, with IL-12 and anti-IL-4 or IL-4, anti-IFN-c, and anti-IL-12 respectively for 5 days, restimulated at day 5 and split
in cultures with and without TGF-b or anti-TGF-b for 5 more days of stimulation. (A, C and D) qRT-PCR gene expression analysis of the relative gene
expression of IL-9, GATA3, and Tbet at day 10 relative to the Th0 culture. (B) CT value from qRT-PCR gene expression analysis of the gene PU.1. Each
donor is represented by a specific symbol and connected with a line. Data are from four independent experiments, each with two donors. *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0021695.g003
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assay (Applied Biosystems) specific for either IL-4 (#Hs
99999030_m1), IL-5 (#4327039T), IL-9 (#Hs00174125_m1),
GATA-3 (#Hs00231122_m1), ST2 (#Hs00249389_m1), PU.1
(#Hs00231368_m1), T-bet (#Hs00203436_m1), TGF-b1
(Hs00171257_m1), b-actin (#401846), or huPO (#4326314E).
The mixture was vortexed slightly and run in triplicates in a Taqman
ABI PRISM Sequence 7700 with Sequence Detector v1.7a software
(Applied Biosystems).
Data were analyzed by setting baseline interval and threshold.
The default setting was 3 to 15 cycles for baseline and 10 times
standard deviation for threshold, and analyzed using the DD cycle
threshold (CT) method [18].
A calibrator stock was made by purifying PBMC from four
buffy coats and stimulating different PBMC cultures overnight
with either 5 mg/ml Staphylococcal Enterotoxin B, 5 ng/ml PMA,
1 mM ionomycin all (Sigma), or 1 mg/ml plate-bound anti-CD3
from DAKO (Glostrup, DK). The PBMC were snap-frozen in
liquid nitrogen and RNA was harvested and used in cDNA
synthesis reactions. The cDNA from the three different stimula-
tions were combined and stored at -80uC.
Statistical analysis
Bar graphs are represented as mean +/2 SEM. One-way matched
Bonferroni ANOVA was used for statistical analysis; data from qRT-
PCR and supernatant were log transformed prior to analysis. Statistics
wereperformedusingPrism4.0fromGraphPad(SanDiego,CA,USA).
Results
TGF-b induces IL-9 production in Th1 and Th2 cells
It has been reported that TGF-b inhibits classic Th1 and Th2
skewing, and furthermore induces a Th9 phenotype when added
to Th2 cultures. To confirm this and to additionally investigate
whether TGF-b can induce IL-9 in differentiated Th1 cultures we
developed an in vitro system with delayed addition of TGF-b,t o
established Th1 and Th2 cultures.
The Th1 and Th2 cultures were established at day 5 (Figs. S1B,
C, E and F; S2, B and C), with little secretion and expression of IL-9
in the Th2 cultures (Figs. S1, A and D; S2A). In addition no PU.1
gene expression (Fig. S2D) could be detected in any of the cultures,
nor the active form of TGF-b1 in the supernatant (Fig. S1G) even
though all cultures expressed the TGF-b1 gene (Fig. S2D).
Supplementing the cultures with TGF-b induced increased
production of IL-9 in the Th1 and the Th2 cultures (Fig. 1A).
Additionally, FACS analysis showed an increase in the number of
cells positive for IL-9, in the Th1 cultures with TGF-b (Fig. 2A).
Furthermore did qRT-PCR data show an induction of the IL-9
gene for both the Th1 and Th2 cultures with TGF-b (Fig. 3A). Of
notion most IL-9 positive cells in the Th1 cultures, at day 10, co-
produced IFN-c (Fig. S3). Neutralization of TGF-b by adding
anti-TGF-b to the Th1 and Th2 cultures resulted in similar level
of IL-9 expression, production, and secretion compared to the
classical Th1 and Th2 conditions (Figs. 1A and 3A).
To investigate if the TGF-b induced induction of IL-9 affects
the expression of the Th1, Th2, and Th9 lineage specific master
transcription factors T-bet, GATA-3, and PU.1 respectively, the
cells were analyzed by FACS (Fig. 2B, E and F) and qRT-PCR
(Fig. 3, C and D). No cultures expressed the PU.1 gene (Fig. 3B)
nor any CD4+ cells were found positive, less than 2%, for PU.1 in
all FACS analysed cultures (Fig. 2B) and (data not shown). As
expected for the Th2 cultures, the percentage of GATA-3-positive
cells did not differ between the groups with and without TGF-b or
anti-TGF-b (Fig. 2E); whereas a significant reduction in the
percentage of the master Th1 transcription factor T-bet was
observed in the T-bet-positive cells compared to classical Th1
culture conditions after addition of TGF-b (Fig. 2F). The Tbet gene
expression at day 10 was unchanged by the addition of TGF-b to
the Th1 cultures (Fig. 3D). The qRT-PCR GATA3 gene results
correlated with the intracellular staining, as addition of TGF-b to
the classic Th2 cultures had no influence on the GATA3 gene
expression (Fig. 3C).
The secretion of the classical Th1 and Th2 cytokines IFN-c and
IL-5 was slightly reduced when TGF-b was added to the cultures
(Fig. 1, B and C). The same trend was observed in Fig. 2C and D,
where the percentage of IL-13
+ and IFN-c
+ cells was reduced after
addition of TGF-b. Classical Th1 and Th2 conditions with and
without anti-TGF-b showed comparable percentages of IFN-c and
IL-13
+ cells (Fig. 2, C and D).
Induction of the IL-33 receptor ST2 by IL-4 and IL-33
IL-33 has been associated with skewing of lymph-node-derived
Th2 cells into a more potent subset, secreting higher levels of the
Th2 associated cytokines IL-5 and IL-13 [19].
To examine if CD4+ T cells are responsive to IL-33, and
further, if IL-4 and TGF-b regulate the expression of the
membrane-bound IL-33 receptor (ST2), different CD4+ T cell
cultures were analysed.
Gene expression of ST2 was induced by addition of IL-4
compared to the control Th0 culture (Fig. 4). TGF-b repressed the
IL-4-induced ST2 gene expression, whereas this effect was
overcome when IL-33 was present in the culture (Fig. 4).
Figure 4. Induction of the IL-33 receptor ST2 by IL-4 and IL-33.
Naı ¨ve CD4+ T cells were activated with fibroblast-bound anti-CD3/CD28
for 5 days in presence of either blocking antibodies against IFN-c and
IL-12 (Th0) or these antibodies plus IL-4 (Th2). At day 5, these cultures
were restimulated and split in cultures with and without TGF-b and/or
IL-33 for an additional 5 days of stimulation. qRT-PCR gene expression
analysis of the relative ST2 expression at day 10 to the Th0 culture. Each
donor is represented by a specific symbol and connected with a line.
Data are from four independent experiments, each with two donors.
Horizontal lines represent means. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0021695.g004
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As already shown, TGF-b induces IL-9 in both Th1 and Th2
cultures (Figs. 1A and 3A), but surprisingly, our results (Fig. 5A)
showed that IL-33 introduced to Th2 cultures causes an increase
in IL-9 secretion comparable to the effect of TGF-b. This was not
confirmed on the gene level (Fig. 5B). The combination of TGF-b
and IL-33 potentiates the gene expression and protein secretion of
IL-9 even further compared to the individual effect of the
cytokines (Fig. 5A and B).
In addition to IL-33, two other IL-1 family members IL-1b and
IL-18 were investigated for their capacity to induce IL-9. IL-18
further increased the TGF-b dependent IL-9 secretion (Fig. S3).
IL-1b and IL-18 did however not, like IL-33 have the ability to
induce IL-9 secretion in Th2 cultures with no TGF-b (Fig. S3).
As a control of endogenously produced active TGF-b, cultures
with no addition of TGF-b were compared with those receiving
anti-TGF-b and no differences in IL-9 gene expression, protein
production and secretion were found.
Il-33 induces IL-9 production in human basophils
Human basophils have recently been reported to express the IL-
33 receptor ST2 [6]. In agreement with previous findings, our
results showed increased surface expression of ST2 on basophils
stimulated with IL-3 for 24 h (Fig. 6), whereas IL-33 stimulation
did not influence surface expression of its receptor (Fig. 6).
Nevertheless, basophils stimulated with IL-33 released IL-9 at a
level comparable to that found upon stimulation with IL-3.
Moreover, there was a marked synergy between IL-3 and IL-33 on
the IL-9 release (Fig. 6).
Discussion
The notion of interleukin 9 as a Th2-type cytokine has recently
been challenged by identification of the so-called IL-9-producing
Th9 cells that express very few, if any, of the Th2-type cytokines
(reviewed in [20]). Other sources of IL-9 may be Th17 cells and
mast cells, and this suggests that the cytokine plays an important
role in moderating local inflammation. A recent paper suggests
that while IL-9 plays only a marginal role in modulating the
inflammation in an acute asthma model, there seems to be a more
profound effect in a model of chronic asthma with repeated
allergen challenges. In the chronic model, IL-9 controls the
remodeling process with mucus production, increased number of
mast cells, increased collagen deposition, and ultimately smooth
muscle cell hypertrophy [10], These and other findings may
indicate that tissue-specific factors are responsible for the transition
from an acute to a chronic form of inflammation, and this
prompted us to study the regulation of IL-9 by tissue-specific
factors such as TGF-b, IL-1b, IL-18 and IL-33.
To model lymph node T-cell differentiation, temporally
separated from tissue factors, we used a 10- day culture protocol
by which classical T helper-cell factors defining Th1 and Th2 were
added at day 0 and the tissue-specific factors TGF-b, IL-1b, IL-18,
and IL-33 after a 5-day interval. Read-out was made at day 10.
Using this human in vitro system, we have confirmed (Fig. 5, A
and B) the results obtained in mice: IL-33 can induce IL-9
expression and secretion in T cells [21]. While others have
reported [16,17] that TGF-b is a critical factor for IL-9 induction,
our results, to the best of our knowledge, for the first time indicate
that TGF-b may be important but is not an absolute requirement
for IL-9 induction, since cultures with IL-33 without TGF-b have
markedly increased secretion of IL-9, suggesting an important role
of IL-33, even though that the effect was not found significant on
the gene level (Fig. 5, A). It has recently been reported [22] that
IL-9 production peaks early after activation, which might explain
why we find a significant increase in the supernatant IL-9 levels
but no difference on its gene expression of the chosen time point.
In future experiments of IL-9 regulation a kinetic study will be
favorable. The TGF-b independent capacity of IL-33 to induce
IL-9, do not seems to be a feature of cytokines in the IL-1 family,
even though we find that IL-18 have an additive effect on IL-9
secretion (Fig. S4) and others have observed the same additive
effect of IL-1b [17].
It has been reported [23,24] that ST2 is selectively upregulated
and expressed on Th2 and not on Th1 or Treg cells; thus, we did
not investigate the influence of IL-33 on other Th subsets. Our
results indicate that TGF-b represses the IL-4 induction of ST2;
however, this effect is overcome by addition of IL-33, which could
be a result of activation of both the IL-4 and IL-33 pathway
overruling the TGF-b repression (Fig. 4).
The surprising induction of IL-9 in differentiated Th1 cultures
was not expected, since reports have indicated a moderate dose-
dependent inhibition of IL-9 secretion by IFN-c in an in vitro
human T cell system [17]. In contrast to this we find most IL-9
positive cells co-produce IFN-c. It has been reported that IL-12
alone or in combination with TGF-b enhances IL-9 secretion and
the percentage of IL-9
+ CD4+ T cells when added to naı ¨ve T cells
day 0, but of notice is that most of the IL-9 positive cells in these
cultures were single positive for either IL-9 or IFN-c [16,17]. The
high concentration of IL-2 in Th1 cultures supplemented with
TGF-b could explain the different results; however, Beriou et al.
showed a non-significant reduction in the percentage of IL-9
+
CD4+ T cells in Th1 cultures without IL-2 compared to Th1 with
added IL-2, indicating that IL-2 is important though not an
absolute requirement for IL-9 induction in Th1 cultures [16]. The
FACS cell number and the mRNA content (data not shown) of the
Th1 cultures with and without TGF-b showed similar levels,
excluding that TGF-b reduced the survival of Th1 cells as the
reason for the reduced expression of Tbet. Culture conditions with
IL-2 and TGF-b have been reported to differentiate CD4+ T cells
into inducible regulatory T cells, but the signature transcription
factor Forkhead box P3 was unfortunately not included in our
FACS staining protocol, making a classification impossible [25].
It has been proposed that TGF-b and IL-4 induce the
expression of a Th9-specific transcription factor PU.1 [14]. PU.1
and GATA proteins can physically and functionally interact,
suggesting that an upregulation of PU.1 might abrogate the
GATA-3 function [26,27]. The physical interaction of PU.1 and
GATA-3 could explain the lower production of IL-5 and reduced
percentage of IL-13- positive cells in the Th2 cultures with TGF-b
(Fig. 1B and 2B). At the gene expression level day 10 after
extraneous addition of TGF-b, no cultures were found to be
Figure 5. A and B. IL-33 and TGF-b induce IL-9 secretion in Th cells. Naı ¨ve CD4+ T cells were activated with fibroblast-bound anti-CD3/CD28
for five 5 days in the presence of blocking antibodies against IFN-c and IL-12 (Th0) or these antibodies plus IL-4 (Th2). At day 5, these cultures were
restimulated and split in cultures with TGF-b or anti-TGF-bplus IL-33 for an additional 5 days of stimulation. (A) Supernatant multiplex analysis of IL-9,
at day 10, after restimulation with PMA and ionomycin for 6 h in the presence of Bref A for the last 4 h. (B) qRT-PCR gene expression analysis of the
relative expression of IL9 at day 10 related to the Th0 culture. Data are from four independent experiments, each with two donors. Vertical lines
represent means (SEM). All tested cultures are significantly different p,0.05 or less compared to Th0 culture. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0021695.g005
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approximately 30 it seems that the used probes anneal to human
PU.1 and thus are functional (data not shown). When compared to
the isotype control, none of the cultures analyzed by FACS for
protein levels of PU.1 were found positive, suggesting that PU.1 is
not the master transcription factor in our culture system. However,
gene and protein analysis at earlier time points is necessary to
exclude the importance of PU.1. Veldhoen et al. report an
Figure 6. ST2 expression and IL-9 secretion from basophils stimulated with IL-3 and IL-33. Analysis of ST2 expression with FACS. Black
line shows surface expression of ST2 on freshly isolated basophils at 0 h; tinted red shows negative control culture without cytokines after 24 h; blue
lines show samples. Example from one donor included in both FACS and multiplex analysis is presented. In total, two independent experiments were
performed, using two donors for each experiment, with similar results. Multiplex analysis of IL-9 in supernatant from a control culture or cultures with
IL-3 and/or IL-33. Data are from two independent experiments, each with two donors. Vertical lines represent means (SEM). **p,0.01.
doi:10.1371/journal.pone.0021695.g006
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secretion, though it is not specifically upregulated in Th9 cells
but by most CD4+ T cells subsets, making it less suitable as a
specific IL-9 marker as PU.1 [15,28].
In agreement with other findings [12,29,30], TGF-b was shown
to mediate repression of the Th1- and Th2-associated cytokines
IFN-c or IL-4, IL-5 and IL-13 (Figs. 1 and 2). This is further
substantiated by a reduced number of CD4
+T-bet
+ cells in the
Th1 cultures (Fig. 2F).
It has been reported that supplementing TGF-b results in
unaffected or reduced expression of the Th2 master transcription
factor GATA-3 [16,17]. Partly in agreement with this, and in
parallel with Wong et al., we find that the GATA3 expression is
unaffected by the supplement of TGF-b to the Th2 cultures
(Figs. 2E and 3C). The unexpectedly high percentage of IL-13-
positive cells in the classical Th1 cultures could be a result of the
addition of IL-2, which activates STAT5, and the low strength T
cell receptor activation [1]. In addition to some CD4+ T cell
subsets, various other cell types have also been reported to produce
IL-9, including murine mast cells [31,32]. Since mast cells and
basophils share various functional features, we wanted to test
whether human basophils secrete IL-9 under the influence of IL-3,
a potent activator and modulator of basophil survival and
differentiation, with and without IL-33 [33,34]. We found that
both cytokines induced IL-9 secretion and, in combination, the
secretion was markedly increased. This is probably due to IL-3-
mediated upregulation of ST2, thereby making the basophils more
responsive to IL-33 (Fig. 6). It has previously been shown that IL-
33 induces expression of the main Th2-associated cytokines IL-4,
IL-5, and IL-13 in human basophils, and that IL-3 act
synergistically, supporting our observations [35]. One interesting
aspect is the IL-9 secretion mediated by IL-33 in the absence of
detectable ST2 expression. However, this is similar to previous
findings [6,35,36] that even though surface expression of ST2
cannot be detected on freshly isolated basophils, these can still be
activated by IL-33. Although we were not able to detect mRNA
expression of neither ST2 nor IL-9, possibly due to the low
number of cells, it should be mentioned that Suzukawa et al. [36]
measured upregulation of ST2 mRNA in basophils stimulated
with IL-33.
Taken together, these results indicate that the expression of IL-9
reflects a more general adaptation of the extravasated cells to
specific cytokines in the microenvironment, resulting in a
heterogeneous pool of IL-9-expressing cells. Therefore, the newly
described association of IL-9 in the process of airway remodeling
in chronic asthma highlights the need for in vivo experiments.
Supporting Information
Figure S1 Established Th1 and Th2 cultures at day 5.
Naı ¨ve CD4
+ T cells were activated with fibroblast-bound anti-
CD3/CD28 under Th0, Th1, and Th2 conditions for 5 days.
Before analysis all cultures were restimulated with PMA and
ionomycin for 6 h in the presence of Bref A for the last 4 h. (A, B
and C) FACS analysis of percentage positive LIVE+CD4+cells for,
respectively IL-9, GATA-3, and T-bet. (D, E, F and G) Multiplex
analysis of supernatant concentrations of IL-9, IL-5, IFN-c, and
active TGF-b1. Data are from two independent experiments, each
with two donors. Horizontal lines represent means.
(TIF)
Figure S2 Gene expression of established Th1 and Th2
cultures at day 5. Naı ¨ve CD4
+ T cells were activated with
fibroblast-bound anti-CD3/CD28 under Th0, Th1, and Th2
conditions for 5 days. (A, B and C) qRT-PCR gene expression
analysis of the relative expression of IL-9, GATA3, and Tbet relative
to the control Th0 culture stimulated with IL-2. (A and B) CT
value from qRT-PCR gene expression analysis of the genes PU.1
and TGF-b1. Data are from two independent experiments, each
with two donors. Horizontal lines represent means.
(TIF)
Figure S3 Th1 cells co-produce IL-9. Naı ¨ve CD4+ T cells
were activated with fibroblast-bound anti-CD3/CD28 under
classical Th1 conditions for 5 days, restimulated at day 5 with
addition of TGF-b for 5 more days of stimulation. A representative
dot plot diagram of the Th1 cultures percentage positive IL-9 and
IFN-c cells.
(TIF)
Figure S4 IL-1 family member IL-18 induces IL-9
secretion in Th9 cells. Naı ¨ve CD4
+ T cells were activated
with fibroblast-bound anti-CD3/CD28 for five 5 days in the
presence of blocking antibodies against IFN-c and IL-12 plus IL-4
(Th2). At day 5, these cultures were restimulated with TGF-b or
anti-TGF-b plus IL-1b, IL-18, IL-33 for an additional 5 days of
stimulation. Supernatant multiplex analysis of IL-9, at day 10,
after restimulation with PMA and ionomycin for 6 h in the
presence of Bref A for the last 4 h. Data are from two independent
experiments, each with two donors. Vertical lines represent means
(SEM). p ,0.05. *p,0.05, **p,0.01, ***p,0.001.
(TIF)
Acknowledgments
We like to thank Christine Møller for her helpful review of the manuscript.
Author Contributions
Conceived and designed the experiments: LB BCP BMJ AH LKP.
Performed the experiments: LB BCP. Analyzed the data: LB BCP BMJ
LKP. Contributed reagents/materials/analysis tools: LKP. Wrote the
paper: LB BCP BMJ AH LKP.
References
1. Zhu JF, Yamane H, Paul WE (2010) Differentiation of Effector CD4 T Cell
Populations. Annual Review of Immunology, Vol 28 28: 445–489. DOI
10.1146/annurev-immunol-030409-101212.
2. Saenz SA, Taylor BC, Artis D (2008) Welcome to the neighborhood: epithelial
cell-derived cytokines license innate and adaptive immune responses at mucosal
sites. Immunological Reviews 226: 172–190.
3. LiewFY,PitmanNI,McInnesIB(2010)Disease-associatedfunctionsofIL-33:thenewkid
inthe IL-1 family. Nature Reviews Immunology 10: 103–110. DOI 10.1038/nri2692.
4. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G (2007) Cutting edge: The
ST2 ligand IL-33 potently activates and drives maturation of human mast cells.
J Immunol 179: 2051–2054. 179/4/2051 [pii].
5. Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C (2010) Regulation
of IL-9 expression by IL-25 signaling. Nature Immunology 11: 250–2U9. DOI
10.1038/ni.1846.
6. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA (2009)
Human basophils and eosinophils are the direct target leukocytes of the novel IL-1
family member IL-33. Blood 113: 1526–1534. DOI 10.1182/blood-2008-05-157818.
7. Schmitz J, Owyang A, Oldham E, Song YL, Murphy E, et al. (2005) IL-33, an
interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2
and induces T helper type 2-associated cytokines. Immunity 23: 479–490. DOI
10.1016/j.immuni.2005.09.015.
8. Lamkanfi M, Dixit VM (2009) IL-33 Raises Alarm. Immunity 31: 5–7. DOI
10.1016/j.immuni.2009.06.011.
9. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM (2009)
Interleukin-33-cytokine of dual function or novel alarmin? Trends in
Immunology 30: 227–233. DOI 10.1016/j.it.2009.03.003.
10. Kearley J, Erjefalt JS, Andersson C, Benjamin E, Jones CP, et al. (2010) IL-9
Governs Allergen-induced Mast Cell Numbers in the Lung and Chronic
IL-33 Induces IL-9 in Human Th Cells and Basophils
PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e21695Remodeling of the Airways. Am J Respir Crit Care, Doi: 10.1164/rccm.200909-
1462OC. In press.
11. McMillan SJ, Xanthou G, Lloyd CM (2005) Manipulation of allergen-induced
airway remodeling by treatment with anti-TGF-beta antibody: Effect on the
Smad signaling pathway. Journal of Immunology 174: 5774–5780.
12. Schmitt E, Germann T, Goedert S, Hoehn P, Huels C, et al. (1994) Il-9
Production of Naive Cd4(+) T-Cells Depends on Il-2, Is Synergistically
Enhanced by A Combination of Tgf-Beta and Il-4, and Is Inhibited by Ifn-
Gamma. Journal of Immunology 153: 3989–3996.
13. Li HM, Rostami A (2010) IL-9: Basic Biology, Signaling Pathways in CD4+T
Cells and Implications for Autoimmunity. Journal of Neuroimmune Pharma-
cology 5: 198–209. DOI 10.1007/s11481-009-9186-y.
14. Chang HC, Sehra S, Goswami R, Yao WG, Yu Q, et al. (2010) The
transcription factor PU.1 is required for the development of IL-9-producing T
cells and allergic inflammation. Nature Immunology 11: 527–U98. DOI
10.1038/ni.1867.
15. Veldhoen M (2010) Interferon Regulatory Factor 4: Combinational Control of
Lymphocyte Differentiation. Immunity 33: 141–143. DOI 10.1016/j.im-
muni.2010.08.007.
16. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, et al. (2010)
TGF-beta Induces IL-9 Production from Human Th17 Cells. Journal of
Immunology 185: 46–54. DOI 10.4049/jimmunol.1000356.
17. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, et al. (2010)
Regulation of human Th9 differentiation by type I interferons and IL-21.
Immunology and Cell Biology 88: 624–631. DOI 10.1038/icb.2010.53.
18. Slack JL, Bi WL, Livak KJ, Beaubier N, Yu M, et al. (2001) Pre-clinical
validation of a novel, highly sensitive assay to detect PML-RAR alpha mRNA
using real-time reverse-transcription polymerase chain reaction. Journal of
Molecular Diagnostics 3: 141–149.
19. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, et al.
(2008) IL-33 induces antigen-specific IL-5(+) T cells and promotes allergic-
induced airway inflammation independent of IL-4. Journal of Immunology 181:
4780–4790.
20. Noelle RJ, Nowak EC (2010) Cellular sources and immune functions of
interleukin-9. Nature Reviews Immunology 10: 683–687. DOI 10.1038/
nri2848.
21. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK (2008) IL-33, a
potent inducer of adaptive immunity to intestinal nematodes. Journal of
Immunology 180: 2443–2449.
22. Tan C, Aziz MK, Lovaas JD, Vistica BP, Shi G, et al. (2010) Antigen-specific
Th9 cells exhibit uniqueness in their kinetics of cytokine production and short
retention at the inflammatory site. J Immunol 185: 6795–6801.
23. Lecart S, Lecointe N, Subramaniam A, Alkan S, Ni DH, et al. (2002) Activated,
but not resting human Th2 cells, in contrast to Th1 and T regulatory cells,
produce soluble ST2 and express low levels of ST2L at the cell surface.
European Journal of Immunology 32: 2979–2987.
24. Xu D, Chan WL, Leung BP, Huang FP, Wheeler R, et al. (1998) Selective
expression of a stable cell surface molecule on type 2 but not type 1 helper T
cells. Journal of Experimental Medicine 187: 787–794.
25. Putheti P, Awasthi A, Popoola J, Gao WD, Strom TB (2010) Human CD4(+)
Memory T Cells Can Become CD4(+)IL-9(+) T Cells. Plos One 5: ARTN
e8706;DOI 10.1371/journal.pone.0008706.
26. Rekhtman N, Radparvar F, Evans T, Skoultchi AI (1999) Direct interaction of
hematopoietic transcription factors PU.1 and GATA-1: functional antagonism
in erythroid cells. Genes & Development 13: 1398–1411.
27. Zhang P, Behre G, Pan J, Iwama A, Wara-Aswapati N, et al. (1999) Negative
cross-talk between hematopoietic regulators: GATA proteins repress PU.1.
Proceedings of the National Academy of Sciences of the United States of
America 96: 8705–8710.
28. Chang HC, Zhang SM, Thieu VT, Slee RB, Bruns HA, et al. (2005) PU.1
expression delineates heterogeneity in primary Th2 cells. Immunity 22:
693–703.
29. Gorelik L, Constant S, Flavell RA (2002) Mechanism of transforming growth
factor beta-induced inhibition of T helper type 1 differentiation. Journal of
Experimental Medicine 195: 1499–1505. DOI 10.1084/jem.20012076.
30. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, et al. (2008)
Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2
cells and promotes an interleukin 9-producing subset. Nature Immunology 9:
1341–1346. DOI 10.1038/ni.1659.
31. Hultner L, Kolsch S, Stassen M, Kaspers U, Kremer JP, et al. (2000) In
activated mast cells, IL-1 up-regulates the production of several Th2-related
cytokines including IL-9. Journal of Immunology 164: 5556–5563.
32. Wiener Z, Falus A, Toth S (2004) IL-9 increases the expression of several
cytokines in activated mast cells, while the IL-9-induced IL-9 production is
inhibited in mast cells of histamine-free transgenic mice. Cytokine 26: 122–130.
DOI 10.1016/j.cyto.2004.01.006.
33. Haakfrendscho M, Arai N, Arai KI, Baeza ML, Finn A, et al. (1988) Human
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor and Inter-
leukin-3 Cause Basophil Histamine-Release. Journal of Allergy and Clinical
Immunology 81: 224.
34. Yamaguchi M, Hirai K, Morita Y, Takaishi T, Ohta K, et al. (1992)
Hematopoietic Growth-Factors Regulate the Survival of Human Basophils
Invitro. International Archives of Allergy and Immunology 97: 322–329.
35. Smithgall MD, Comeau MR, Yoon BRP, Kaufman D, Armitage R, et al. (2008)
IL-33 amplifies both T(h)1-and T(h)2-type responses through its activity on
human basophils, allergen-reactive T(h)2 cells, iNKT and NK Cells.
International Immunology 20: 1019–1030. DOI 10.1093/intimm/dxn060.
36. Suzukawa M, Likura M, Koketsu R, Nagase H, Tamura C, et al. (2008) An IL-1
Cytokine Member, IL-33, Induces Human Basophil Activation via Its ST2
Receptor. Journal of Immunology 181: 5981–5989.
IL-33 Induces IL-9 in Human Th Cells and Basophils
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e21695